US Food and Drug Administration advisors voted unanimously in favor of expanding the use of Janssen Biotech Inc.’s CAR-T Carvykti to earlier lines of multiple myeloma treatment, saying the benefit of a potential long durable response that allows patients time off toxic treatment outweighs the upfront risks of treatment initiation.
In a separate 8-3 vote, the Oncologic Drugs Advisory Committee also voted that Celgene Corporation's (Bristol Myers Squibb Company) CAR-T therapy Abecma has a positive benefit-risk assessment in earlier lines of treatment for multiple myeloma, although panelists raised some concerns about the lack of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?